Kubota Pharma to raise $11,500 in stock-rights placement
What's the deal? Kubota Pharmaceutical Holdings Co., Ltd. announced a private placement expected to raise US$13.8K, issuing two series of stock-acquisition rights to Evo Fund and individual investor Ryo Kubota. The company disclosed the deal on October 23, 2026, with closing expected from November 9, 2026.
What are the terms? It will issue 200,000 of its 41st Series rights at US$0.06 each — US$12.3K in gross proceeds — to Evo Fund, which is sponsored by Evolution Capital Management LLC. Ryo Kubota takes 200,000 of the 42nd Series rights at US$0.01 each, for US$1.54K. Both carry an initial exercise price of US$0.46 per share.
Why now? Kubota Pharma is under persistent financial pressure. In the six months to June 2026, revenue was US$61.5K and net loss widened to US$4.99M, with operating cash flow still negative.
It held US$12.2M in cash and financial instruments at June-end but said it continued to weigh financing measures. The company also raised funds through exercised stock-acquisition rights in 2025 and the first half of 2026.
What's the endgame? The company is advancing emixustat, including GMP manufacturing and a France-focused compassionate-use effort, while it seeks partners for further development.
The signal: The US$13.8K figure reflects only the proceeds from issuing the rights — not the larger sum that could follow if investors exercise them. As a small financing event resolved through third-party allocation and board approval, it underlines Kubota Pharma's continued reliance on securities issuance to fund a cash-burning pipeline.
Read more: ae.marketscreener.com
Image credit: Generated with Gemini
